Scientists hunt for hidden signs in blood cancers to personalize treatment

NCT ID NCT02320656

Completed Knowledge-focused Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict how the disease will progress or respond to treatment. The goal is to better understand these cancers and improve personalized care in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict how blood cancers will behave and which treatments might work best for each patient.
What could go wrong: This is an observational study, not a treatment trial. It collects samples to learn more, but may not directly lead to new therapies or change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROMES MYELOPROLIFERATIVE DISORDERS

Contacts and locations

Locations

Institut Paoli-Calmettes

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.